Developer · United States

Reunion Neuroscience Inc.

Private clinical-stage biopharmaceutical company headquartered in Morristown, New Jersey, developing serotonergic psychedelic therapeutics for underserved mental health disorders. Formerly the drug-discovery arm of Field Trip Health (its legacy compound code FT-104 survives in chemical registries) and previously Nasdaq-listed; taken private by MPM BioImpact in an August 2023 plan of arrangement, then financed with a $103 million Series A co-led by MPM BioImpact and Novo Holdings in May 2024, upsized to $133 million at final close in September 2025. Lead asset is luvesilocin (RE104), a subcutaneous prodrug of 4-OH-DiPT in postpartum depression (FDA Breakthrough Therapy designation, Phase 3-ready), adjustment disorder and generalized anxiety disorder; a discovery-stage non-hallucinogenic oral 5-HT2A agonist, RE245, sits behind it.

reunionneuro.com ↗

1compound
2programs
2indications
Phase 2lead asset

Phase distribution

  • Phase 22

Modality

  • Psychedelic 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • Sep 16, 2025FinancingSeries A final close upsized to $133 million on RECONNECT efficacy; GAD program fundedReunion announced the final closing of its Series A. Because RECONNECT met prespecified efficacy parameters, the final tranche increased from $21 million to $51 million, bringing the total Series A to $133 million from the $103 million announced in May 2024. Proceeds fully fund the ongoing REKINDLE Phase 2 in adjustment disorder and expand RE104 into generalized anxiety disorder via the RECLAIM Phase 2 trial.Luvesilocin (RE104)source ↗
  • May 2, 2024FinancingReunion Neuroscience raises $103 million Series A co-led by MPM BioImpact and Novo HoldingsSeries A financing of $103 million co-led by MPM BioImpact and Novo Holdings, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures and Palo Santo. Proceeds were earmarked for the RECONNECT Phase 2 trial of RE104 in postpartum depression and for expansion into adjustment disorder in cancer.Luvesilocin (RE104)source ↗
  • Aug 1, 2023AcquisitionMPM BioImpact completes take-private acquisition of Reunion NeuroscienceReunion Neuroscience and MPM BioImpact announced completion of the plan of arrangement, taking the Nasdaq-listed company private under a US$13.1 million transaction first announced on 2023-06-01. Shareholders approved the arrangement on 2023-07-13 and the final court order followed on 2023-07-14. The take-private is what set up the $103 million Series A nine months later and the resources to run RECONNECT.Luvesilocin (RE104)source ↗

Catalysts · 2 upcoming · 2 reported

Recently reported

  • 2026-01-20met

    Luvesilocin (RE104)forPostpartum depressionFull results

    Full RECONNECT Phase 2 dataset presented at the ACNP Annual Meeting: MADRS separation from Day 1 sustained through Day 28, plus response, remission, HAM-A, CGI-I and Barkin Index of Maternal Function improvements, from a baseline MADRS of 33.4.

    source ↗

  • 2025-08-18met

    Luvesilocin (RE104)forPostpartum depressionTopline data

    RECONNECT Phase 2 topline in postpartum depression: a single 30 mg subcutaneous dose of RE104 met the primary endpoint with a 23.0-point MADRS reduction at Day 7 vs 17.2 points on 1.5 mg active control (difference 5.80; one-sided p=0.0094), with 77.1% response and 71.4% remission at Day 7 and no serious adverse events.

    source ↗

Recent activity

  • Apr 20, 2026Phase changeLuvesilocin (RE104)·Generalized anxiety disorderPhase 2RECLAIM (NCT07489651, RE104-203-GAD) actual study start per ClinicalTrials.gov; status recruiting, record last updated 2026-06-26. Slipped roughly one quarter against the guided Q1 2026 initiation reiterated in the 2025-09-16 financing release and the 2026-01-12 milestones release. Reunion has never publicly characterised this as a delay.source ↗
  • Feb 23, 2026Phase changeLuvesilocin (RE104)·Postpartum depressionPhase 2Program returns to active, pre-Phase-3, after the positive Phase 2: FDA granted Breakthrough Therapy designation for luvesilocin in PPD, following a December 2025 End-of-Phase-2 meeting at which FDA indicated that a single additional successful Phase 3 trial would complete the pivotal package required for registration. Reunion guides to initiating that Phase 3 in 2026. NOT recorded as phase_3 — no Phase 3 study is registered under this sponsor and no initiation has been announced as of 2026-07-24.source ↗
  • Jan 20, 2026ReadoutLuvesilocin (RE104)·Postpartum depressionmetFull RECONNECT Phase 2 dataset presented at the ACNP Annual Meeting: MADRS separation from Day 1 sustained through Day 28, plus response, remission, HAM-A, CGI-I and Barkin Index of Maternal Function improvements, from a baseline MADRS of 33.4.source ↗
  • Sep 16, 2025Phase changeLuvesilocin (RE104)·Generalized anxiety disorderUnknownProgram created and funded, before any trial existed: on final close of its Series A — upsized to $133 million because RECONNECT met prespecified efficacy parameters in PPD — Reunion announced plans to advance RE104 into clinical development for generalized anxiety disorder via a multicenter, randomized, double-blind, dose-controlled Phase 2 (RECLAIM) with a HAM-A Week 4 primary endpoint, guided to start in Q1 2026. Phase recorded as 'unknown' rather than 'phase_2' because on this date no GAD study had been designed into the registry and no patient had been dosed in this indication.source ↗
  • Aug 18, 2025ReadoutLuvesilocin (RE104)·Postpartum depressionmetRECONNECT Phase 2 topline in postpartum depression: a single 30 mg subcutaneous dose of RE104 met the primary endpoint with a 23.0-point MADRS reduction at Day 7 vs 17.2 points on 1.5 mg active control (difference 5.80; one-sided p=0.0094), with 77.1% response and 71.4% remission at Day 7 and no serious adverse events.source ↗
  • May 22, 2025Phase changeLuvesilocin (RE104)·Postpartum depressionPhase 2RECONNECT actual primary completion per ClinicalTrials.gov (actual study completion 2025-06-16); Reunion announced last patient dosed on 2025-05-19, on schedule, with topline guided to 3Q 2025. Enrollment closed at 84 patients across 38 US sites.source ↗
  • Jun 14, 2024Phase changeLuvesilocin (RE104)·Postpartum depressionPhase 2RECONNECT (NCT06342310, RE104-201-PPD) actual study start per ClinicalTrials.gov — a multicenter, randomized, triple-masked, parallel-group dose-controlled Phase 2 of a single subcutaneous dose of RE104 30 mg vs 1.5 mg active control in moderate-to-severe PPD, primary endpoint change from baseline in MADRS total score at Day 7. Reunion separately announced first patient dosed on 2024-07-23; the registry's actual start date is used here and the roughly five-week gap is unexplained by either source.source ↗

Trials recruiting · 2 recruiting of 4 sponsored

  • Phase 2Luvesilocin (RE104)n=6412 sites · United States

    A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder — RECLAIM

    Generalized Anxiety DisorderNCT07489651 ↗

  • Phase 2RE104 for Injectionn=10030 sites · United States

    RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    Adjustment DisorderNCT07002034 ↗

Competitive landscape

Other companies developing against Reunion Neuroscience Inc.'s targets or indications.